{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T22:44:50Z","timestamp":1759099490650},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.hrthm.2008.01.023","type":"journal-article","created":{"date-parts":[[2008,1,31]],"date-time":"2008-01-31T11:36:17Z","timestamp":1201779377000},"page":"S26-S31","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S","title":["Pharmacotherapy for atrial arrhythmias: Present and future"],"prefix":"10.1016","volume":"5","author":[{"given":"Michael J.","family":"Mazzini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Monahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2008.01.023_bib1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","article-title":"Epidemiologic features of chronic atrial fibrillation: the Framingham study","volume":"306","author":"Kannel","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.eurheartj.a062497","article-title":"A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation","volume":"9","author":"Lewis","year":"1988","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2008.01.023_bib3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/hrt.72.2.161","article-title":"Functional capacity before and after cardioversion of atrial fibrillation: a controlled study","volume":"72","author":"Gosselink","year":"1994","journal-title":"Br Heart J"},{"key":"10.1016\/j.hrthm.2008.01.023_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","article-title":"Impact of atrial fibrillation on the risk of death: the Framingham Heart Study","volume":"98","author":"Benjamin","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.hrthm.2008.01.023_bib7","first-page":"698","article-title":"Management of atrial fibrillation: the need for AFFIRMative action","volume":"84","author":"Waldo","year":"1999","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib8","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJM200104053441407","article-title":"Atrial fibrillation","volume":"344","author":"Falk","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib9","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib10","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","article-title":"A comparison of rate control and rhythm control in patients with atrial fibrillation","volume":"347","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib11","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/01.CIR.0000118472.77237.FA","article-title":"Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study","volume":"109","author":"Steinberg","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa021375","article-title":"A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation","volume":"347","author":"Van Gelder","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejheart.2007.12.004","article-title":"Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF-CHF, HART, MASTER, POISE and stem cell therapy","volume":"10","author":"Cleland","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrthm.2008.01.023_bib14","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/01.CIR.82.4.1106","article-title":"Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion","volume":"82","author":"Coplen","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0735-1097(92)90003-6","article-title":"Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation","volume":"20","author":"Flaker","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study","volume":"109","author":"Corley","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib17","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent-onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"issue":"3 Suppl","key":"10.1016\/j.hrthm.2008.01.023_bib19","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.hrthm.2006.12.027","article-title":"Nonantiarrhythmic drug therapy for atrial fibrillation","volume":"4","author":"Murray","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2008.01.023_bib20","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1476-5381.1970.tb09891.x","article-title":"The effect of amiodarone, a new anti-anginal drug, on cardiac muscle","volume":"39","author":"Singh","year":"1970","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.RES.29.3.286","article-title":"Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle","volume":"29","author":"Singh","year":"1971","journal-title":"Circ Res"},{"key":"10.1016\/j.hrthm.2008.01.023_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0002-8703(74)90080-5","article-title":"Comparative mechanisms of action of antiarrhythmic drugs","volume":"87","author":"Singh","year":"1974","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2008.01.023_bib23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM200003303421302","article-title":"Amiodarone to prevent recurrence of atrial fibrillation","volume":"342","author":"Roy","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJM198702193160807","article-title":"Amiodarone","volume":"316","author":"Mason","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2008.01.023_bib25","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0735-1097(97)00220-9","article-title":"Adverse effects of low dose amiodarone: a meta-analysis","volume":"30","author":"Vorperian","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00005344-199509000-00016","article-title":"SR 33589, a new amiodarone-like agent: effect on ischemia- and reperfusion-induced arrhythmias in anesthetized rats","volume":"26","author":"Manning","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib27","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1161\/01.CIR.100.22.2276","article-title":"Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone","volume":"100","author":"Sun","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib28","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"N Engl J Med"},{"author":"Kober","key":"10.1016\/j.hrthm.2008.01.023_bib29"},{"key":"10.1016\/j.hrthm.2008.01.023_bib31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00005344-200408000-00015","article-title":"In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects","volume":"44","author":"Gautier","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.fjc.0000151899.03379.76","article-title":"In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias","volume":"45","author":"Gautier","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00003495-199856050-00003","article-title":"Is there a future for antiarrhythmic drug therapy?","volume":"56","author":"Guerra","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.hrthm.2008.01.023_bib34","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1161\/01.CIR.103.23.2851","article-title":"Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall","volume":"103","author":"Yan","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib35","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1161\/01.CIR.0000143050.22291.2E","article-title":"\u201cEarly\u201d class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat","volume":"110","author":"Blaauw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib36","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.106.630905","article-title":"AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat","volume":"114","author":"de Haan","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib37","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1161\/CIRCULATIONAHA.105.575332","article-title":"The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation","volume":"112","author":"Dobrev","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib38","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/CIRCULATIONAHA.105.561738","article-title":"Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias","volume":"113","author":"Cha","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1254\/jphs.FP0060324","article-title":"Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1\/4 channel","volume":"101","author":"Matsuda","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.hrthm.2008.01.023_bib40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/europace\/eum018","article-title":"NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs","volume":"9","author":"Hashimoto","year":"2007","journal-title":"Europace"},{"key":"10.1016\/j.hrthm.2008.01.023_bib41","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1124\/mol.107.039388","article-title":"The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels","volume":"72","author":"Eldstrom","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib42","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2004.09.021","article-title":"A randomized, controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation","volume":"44","author":"Roy","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/00126839-200708040-00007","article-title":"Vernakalant: RSD 1235, RSD-1235, RSD1235","volume":"8","year":"2007","journal-title":"Drugs R D"},{"key":"10.1016\/j.hrthm.2008.01.023_bib45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/FJC.0b013e3180547553","article-title":"The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans","volume":"50","author":"Dorian","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib48","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib49","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","article-title":"Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine","volume":"116","author":"Burashnikov","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1054-8807(01)00078-3","article-title":"The role of myocardial gap junctions in electrical conduction and arrhythmogenesis","volume":"10","author":"Kanno","year":"2001","journal-title":"Cardiovasc Pathol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/01.RES.88.3.333","article-title":"Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43","volume":"88","author":"Gutstein","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.hrthm.2008.01.023_bib52","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1540-8167.1998.tb00940.x","article-title":"Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat","volume":"9","author":"van der Velden","year":"1998","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/01.CIR.103.6.842","article-title":"The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation","volume":"103","author":"Dupont","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0735-1097(01)01443-7","article-title":"Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria","volume":"38","author":"Polontchouk","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0008-6363(02)00273-0","article-title":"Structural correlate of atrial fibrillation in human patients","volume":"54","author":"Kostin","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrthm.2008.01.023_bib56","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.cell.2006.12.037","article-title":"Microtubule plus-end-tracking proteins target gap junctions directly from the cell interior to adherens junctions","volume":"128","author":"Shaw","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.hrthm.2008.01.023_bib57","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1540-8167.2003.02329.x","article-title":"ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs","volume":"14","author":"Xing","year":"2003","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib58","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1161\/01.CIR.0000101926.43759.10","article-title":"Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy","volume":"108","author":"Eloff","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib59","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.106.665547","article-title":"Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs","volume":"115","author":"Shiroshita-Takeshita","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200519030-00003","article-title":"Oral delivery of peptide drugs: barriers and developments","volume":"19","author":"Hamman","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.hrthm.2008.01.023_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01792-8","article-title":"Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations","volume":"470","author":"Ta\u1e31","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib62","doi-asserted-by":"crossref","first-page":"39D","DOI":"10.1016\/S0002-9149(02)03378-7","article-title":"Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues","volume":"91","author":"Wolbrette","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2008.01.023_bib63","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.CIR.0000051455.44919.73","article-title":"Asymptomatic or \u201csilent\u201d atrial fibrillation frequency in untreated patients and patients receiving azimilide","volume":"107","author":"Page","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2008.01.023_bib64","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/eurheartj\/ehl209","article-title":"Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial","volume":"27","author":"Lombardi","year":"2006","journal-title":"Eur Heart J"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527108000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527108000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T11:34:22Z","timestamp":1557228862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527108000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S1547527108000994"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2008.01.023","relation":{},"ISSN":["1547-5271"],"issn-type":[{"type":"print","value":"1547-5271"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}